BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30936096)

  • 1. Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms.
    Arends SJR; Rhomberg PR; Cotroneo N; Rubio A; Flamm RK; Mendes RE
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary Evaluation of Tebipenem
    Mendes RE; Arends SJR; Streit JM; Critchley I; Cotroneo N; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0205722. PubMed ID: 36625644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Tebipenem Hydrolysis by β-Lactamases Prevalent in Complicated Urinary Tract Infections.
    Sun Z; Su L; Cotroneo N; Critchley I; Pucci M; Jain A; Palzkill T
    Antimicrob Agents Chemother; 2022 May; 66(5):e0239621. PubMed ID: 35491852
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Mendes RE; Rhomberg PR; Lister T; Cotroneo N; Parr TR; Castanheira M
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
    Castanheira M; Mills JC; Costello SE; Jones RN; Sader HS
    Antimicrob Agents Chemother; 2015; 59(6):3509-17. PubMed ID: 25845862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
    Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
    Fritsche TR; Stilwell MG; Jones RN
    Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Lacasse E; Brouillette E; Larose A; Parr TR; Rubio A; Malouin F
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile.
    Wozniak A; Villagra NA; Undabarrena A; Gallardo N; Keller N; Moraga M; Román JC; Mora GC; García P
    J Med Microbiol; 2012 Sep; 61(Pt 9):1270-1279. PubMed ID: 22700549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the
    Ranasinghe A; Henderson A; Cottrell K; Tan CSE; Burnard D; Kato H; Paterson DL; Harris PNA
    JAC Antimicrob Resist; 2022 Oct; 4(5):dlac105. PubMed ID: 36196442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
    Mendes RE; Rhomberg PR; Bell JM; Turnidge JD; Sader HS
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
    Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
    Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial Activity of Tebipenem and Comparators against Enterobacterales from diverse Outpatient Centers and Nursing Homes in the United States.
    Asempa TE; Bobenchik AM; Bourassa L; Clark AE; Hatch MT; Huse HK; Martin IW; Mochon AB; Munson E; Sfeir MM; Srodon M; Wang Y; Nicolau DP
    Int J Antimicrob Agents; 2023 Mar; 61(3):106733. PubMed ID: 36690122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo activity of tebipenem against ESBL-producing E. coli.
    Thamlikitkul V; Lorchirachoonkul N; Tiengrim S
    J Med Assoc Thai; 2014 Dec; 97(12):1259-68. PubMed ID: 25764632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
    Kiremitci A; Dinleyici EC; Erben N; Durmaz G; Yargic ZA; Aybey AD; Usluer G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1441-9. PubMed ID: 18518776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic and molecular characteristics of carbapenem-non-susceptible Enterobacteriaceae from a teaching hospital in Wenzhou, southern China.
    Zhou T; Zhang X; Guo M; Ye J; Lu Y; Bao Q; Chi W
    Jpn J Infect Dis; 2013; 66(2):96-102. PubMed ID: 23514904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).
    Sader HS; Huband MD; Duncan LR; Flamm RK
    Pediatr Infect Dis J; 2018 Jun; 37(6):549-554. PubMed ID: 29206750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.